FDA Determines Regulatory Review Period for VYALEV Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VYALEV, a human drug product, in accordance with the law, following a submission to the U.S. Patent and Trademark Office (USPTO).